Keywords: Nabi Biopharma, Fresenius USA Manufacturing, Phoslyra, PhosLo, Milestone, Renal disease

Nabi Biopharma gets $5 million milestone under Fresenius accord

Article | 17 August 2011

Print This

In some positive news for US drug developer Nabi Biopharmaceuticals (Nasdaq: NABI), the company said it has received a $5 million ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in